Luis Anarbol Moran: Final Debarment Order
FDA debarred Luis Anarbol Moran for 5 years from importing drugs. Med-spas must verify their injectable supply chain to avoid sourcing from debarred individuals.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All med-spas and aesthetics clinics that purchase injectable drugs (e.g., Botox, dermal fillers) from importers or distributors. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Luis Anarbol Moran is now prohibited from importing or offering drugs for import into the U.S. for 5 years. Any drugs he handled may be adulterated or misbranded.
Who it affects
All med-spas and aesthetics clinics that purchase injectable drugs (e.g., Botox, dermal fillers) from importers or distributors.
What you must do
Review your supply chain to ensure no injectable products were sourced from Moran or his associated entities. If found, stop use and notify FDA.
Deadline
Immediately; ongoing compliance required.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication